Tripolt NJ, et al. - Researchers determined the impacts of the dipeptidylpeptidase-4 inhibitor linagliptin in subjects with coronary artery disease (CAD) but early type 2 diabetes mellitus (T2DM)(postchallenge diabetes (2 h glucose > 200 mg/dl) on a set of cardiovascular surrogate measurements. Change in mean flow mediated dilatation (FMD), arginine bioavailability ratios [Global arginine bioavailability ratio (GABR) and arginine to ornithine ratio (AOR)] as well as on endothelial function were assessed among participants who received either linagliptin (5 mg) once daily orally or placebo for 12 weeks. No significantly different change was evident in mean FMD in the linagliptin group, relative to the placebo group and no significant improvements were seen in the arginine bioavailability ratios. Overall, no improved endothelial function or the arginine bioavailability ratios were attained with linagliptin treatment in subjects with CAD and early T2DM.